E-DRUG: Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
----------------------------------------------------------------------------------------------
Newsletter, February 2019
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
The annual Prescrire Awards are given out in Paris: 5 winning drugs, but no "Pilule d'Or"
The independent French medical journal Prescrire announced its Drug Awards for 2018, at its yearly awards ceremony in Paris on 31 January. There was no "Pilule d'Or" (Golden Pill) award, but two drugs made the "Honours List" and three others were recognised as "Noteworthy".
Read more
--------------------------------------------------------------------------------
The Prescrire Drug Packaging Awards for 2018: no winners and a lot of losers
The independent French medical journal Prescrire held its annual awards ceremony in Paris on 31 January. There were no Packaging Awards this year, whereas 25 "Yellow Cards" or "Red Cards" were handed out for substandard or dangerous packaging.
Read more
--------------------------------------------------------------------------------
Prescrire's Information Awards for 2018: just 7 drug companies (out of 86 contacted) are honoured for the quality of information provided
Prescrire's annual Information Awards recognise drug companies which respond to Prescrire's requests with complete and relevant information. The picture in 2018 was no better than in prior years: only a few drug companies embraced transparency, in the best interest of patients.
Read more
--------------------------------------------------------------------------------
FEATURED REVIEW Simple febrile seizures in a child. First-choice treatments
Febrile seizures occur in around 3% of children. What are the essential points for healthcare professionals to keep in mind? And what are the warning signs to look out for?
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the February issue of Prescrire International: Midostaurin (Rydapt°) for some types of acute myeloid leukaemia
In this month's sample review, Prescrire's editors give this multi-tyrosine kinase inhibitor a rating of "Offers an advantage", but warn that the drug's adverse effects are underestimated.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Glecaprevir + pibrentasvir in chronic hepatitis C * Ribociclib in locally advanced or metastatic breast cancer * High-strength insulins: think and act in units of insulin to prevent errors * Melatonin: a review of adverse effects reported in France...
Subscribe now
Prescrire International <international@prescrire.org>